REGULATORY

Chuikyo Submits Recommendation for FY2018 Reimbursement Policy Reform, Drug Pricing Package Enshrined

February 8, 2018

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Central Social Insurance Medical Council, a key health ministry advisory organ better known as Chuikyo, on February 7 submitted its recommendation for the FY2018 reimbursement policy reform this April, which embraces a package of drug pricing overhauls hammered…

To read the full story

Payers Give High Marks for “Bold” Pricing Reform, but Not Happy with PMP
February 8, 2018
“Unprecedented Reforms to Take Place as a Result of Chuikyo’s Leadership”: JMA Pres. Yokokura
February 8, 2018

REGULATORY

LDP Lawmakers’ League Urges Continued Coverage for Local Transdermal Analgesics
December 10, 2025
Senior LDP Lawmakers Call for “Net Plus” in FY2026 Fee, Drug Price Revisions
December 10, 2025
Japan Govt Council Discusses Draft Recommendations for National MCM Strategy
December 9, 2025
MHLW Eyes Govt-Led Ingredient Lists for Regional Formularies: LDP Briefing
December 9, 2025
JMA Pushes Back on Incentives Tied to Regional Formularies: Chuikyo
December 9, 2025

Chuikyo Debate on FY2026 Drug Pricing Reform

MHLW Floats Deducting Private-Practice Use for Re-Pricing, but Off-Cycle Cuts Possible; GLP-1 Eyed?

Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…